CLAIMS:

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

R^{1a}, R^{1b}, R^{1c}, and R^{1d} are each independently selected from the group consisting of H, halogen, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkoxy, and CN;

X^1 is C_{1-3} alkylene, optionally substituted with one or two C_{1-2} alkyl or CO_2H;

R^{2a} and R^{2b} are each independently selected from the group consisting of H, C_{1-8} alkyl, C_{1-8} haloalkyl, -Y, $-X^2-C(O)_2R^a$, $-X^2-OR^a$, $-X^2-NR^aR^b$, $-X^2-CONR^aR^b$, $-X^2-SO_2R^a$, $-X^2-SO_2NR^aR^b$, $-X^2-SO_3R^a$, and $–X^2$-Y, wherein each X^2 is C_{1-6} alkylene, and any C_{1-8} alkyl or C_{1-6} alkylene is optionally further substituted with one or two members independently selected from OH, SO_2NH_2, $CONH_2$, C(O)NHOH, PO_3H_2, COO-C_{1-8} alkyl, and CO_2H, and each Y is selected from the group consisting of C_{3-6} cycloalkyl, C_{4-8} heterocyclyl, and 5- to 6-membered heteroaryl, each of which is optionally further substituted with one to four substituents independently selected from the group consisting of oxo, OH, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} hydroxyalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, C_{1-4} hydroxyalkoxy, SO_2NH_2, $CONH_2$, C(O)NHOH, PO_3H_2, COO-C_{1-8} alkyl, SO_3H, and CO_2H;

or R^{2a} and R^{2b} are combined to form a 4- to 10-membered ring or spirocyclic ring, optionally having one or two additional ring vertices selected from O, N, and S;

wherein the 4- to 10-membered ring or spirocyclic ring formed by combining R^{2a} and R^{2b} is substituted with 0 to 4 substituents independently selected from the group consisting of oxo, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, $-X^3-C(O)_2R^a$, $-X^3-OR^a$, $-X^3-NR^aR^b$, $-X^3-CONR^aR^b$, $-X^3-SO_2R^a$, $-X^3-SO_2NR^aR^b$, and $–X^3-SO_3R^a$; wherein X^3 is a bond or C_{1-6} alkylene;

R^3 and R^4 are each independently selected from the group consisting of F, Cl, CN, CH_3, OCH_3, CH_2CH_3, and CF_3;

the subscript n is 0, 1, 2, or 3;

each R^{3a} is independently selected from the group consisting of H, F, Cl, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, C_{2-3} alkenyl, and CN;

R^6, R^7, and R^8 are each independently selected from the group consisting of H, F, Cl, CN, CH_3, OCH_3, CH_2CH_3, and CF_3;

A is a member selected from the group consisting of $–N(R^a)-$, $–C(=O)N(R^a)-$, $–S(O)N(R^a)-$, and $–S(O)_2N(R^a)-$;

Z is selected from the group consisting of:

i) a monocyclic, bicyclic, or spirocyclic non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with up to four R^a and/or R^b;

ii) a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three R^c; and

iii) a fused bicyclic heteroaryl ring, optionally substituted with one to three R^c;

wherein when A is $–N(R^a)-$, then Z is a fused bicyclic heteroaryl ring optionally substituted with one to three R^c;

each R^a is independently selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkylene-CO_2H, and C_{1-6} alkylene-SO_3H;

each R^b is independently selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkylene-CO_2H, and C_{1-6} alkylene-SO_3H, each of which is optionally further substituted with one or two members independently selected from OH, SO_2NH_2, $CONH_2$, C(O)NHOH, PO_3H_2, COO-C_{1-8} alkyl, and CO_2H;

and R^a and R^b, when attached to the same nitrogen atom, are optionally combined to form a 4- to 8-membered ring or spirocyclic ring, optionally substituted with halogen, OH, SO_2NH_2, $CONH_2$, C(O)NHOH, PO_3H_2, COO-C_{1-8} alkyl, or CO_2H;

each R^c is independently selected from the group consisting of H, halogen, CN, C_{1-6} alkyl, C_{1-6} haloalkyl, $-Y^1$, $-X^4-C(O)_2R^a$, $-O-X^4-C(O)_2R^a$, $-X^4-OR^a$, $-X^4-NR^aR^b$, $-X^4-CONR^aR^b$, $-O-X^4-CONR^aR^b$, $-X^4-SO_2R^a$, $-X^4-SO_2NR^aR^b$, $-X^4-SO_3R^a$, and $-N(R^a)-X^4-C(O)_2R^a$,

wherein each X^4 is a bond or C_{1-6} alkylene, and each Y^1 is selected from the group consisting of C_{3-6} cycloalkyl and C_{4-8} heterocyclyl; and

optionally two R^c on adjacent ring vertices are combined to form a fused 5- or 6-membered heterocyclic ring.

2. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, having formula (Ia):



(Ia).

3. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, having formula (Ib):



(Ib).

4. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, having formula (Ic):



(Ic).

5. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, having formula (Id):



(Id).

6. The compound of any one of claims **1** to **5,** or a pharmaceutically acceptable salt thereof, wherein the group R^{1a} is OCH_3 and R^{1b} is F.

7. The compound of any one of claims **1** to **5**, or a pharmaceutically acceptable salt thereof, wherein A is –C(=O)N(R^a)-, and Z is selected from the group consisting of:

i) a 5- or 6-membered non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with up to four R^a and/or R^b; and

ii) a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three R^c.

8. The compound of any one of claims **1** to **5**, or a pharmaceutically acceptable salt thereof, wherein Z is a non-aromatic heterocyclic ring having a formula selected from the group consisting of:



.

9. The compound of any one of claims **1** to **5**, or a pharmaceutically acceptable salt thereof, wherein Z is a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three R^c; and said heteroaryl ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, oxazolyl, thiazolyl, and pyrazolyl.

10. The compound of any one of claims **1** to **5**, or a pharmaceutically acceptable salt thereof, wherein Z is a non-aromatic heterocyclic ring selected from the group consisting of piperidinyl, morpholinyl, tetrahydropyranyl, and tetrahydrofuranyl, each of which is optionally substituted with up to four R^a and/or R^b.

11. The compound of any one of claims **1** to **5**, or a pharmaceutically acceptable salt thereof, wherein A is $–N(R^a)-$, and Z is a fused bicyclic heteroaryl ring, optionally substituted with one to three R^c.

12. The compound of claim **1** or **11**, or a pharmaceutically acceptable salt thereof, wherein Z is a fused bicyclic heteroaryl ring having a formula selected from the group consisting of:



and

.

13. The compound of any one of claims **1** to **12**, or a pharmaceutically acceptable salt thereof, wherein R^{2a} and R^{2b} are each H.

14. The compound of any one of claims **1** to **12**, or a pharmaceutically acceptable salt thereof, wherein R^{2a} and R^{2b} are combined to form a 4- to 9-membered ring or spirocyclic ring, optionally having one or two additional ring vertices selected from O, N, and S; wherein said ring or spirocyclic ring is substituted with 0 to 4 substituents independently selected from the group consisting of oxo, C_{1-8} alkyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, $-X^3-C(O)_2R^a$,

$-X^3-OR^a$, $-X^3-NR^aR^b$, $-X^3-CONR^aR^b$, $-X^3-SO_2R^a$, $-X^3-SO_2NR^aR^b$, and $-X^3-SO_3R^a$; wherein X^3 is a bond or C_{1-6} alkylene.

15. The compound of any one of claims **1** to **12**, or a pharmaceutically acceptable salt thereof, wherein $-N(R^{2a})(R^{2b})$ is selected from the group consisting of:



.

16. The compound of any one of claims **1** to **12**, or a pharmaceutically acceptable salt thereof, wherein $-N(R^{2a})(R^{2b})$ is selected from the group consisting of:



.

17. The compound of any one of claims **1** to **12**, or a pharmaceutically acceptable salt thereof, wherein $-N(R^{2a})(R^{2b})$ is selected from the group consisting of:



18. The compound of any one of claims **1** to **12**, or a pharmaceutically acceptable salt thereof, wherein R^{2a} is H or C_{1-8} alkyl; and R^{2b} is –Y or $–X^2$-Y.

19. The compound of any one of claims **1** to **18**, or a pharmaceutically acceptable salt thereof, wherein the compound is an optically pure or enriched isomer.

20. The compound of claim **18**, or a pharmaceutically acceptable salt thereof, wherein Y is selected from the group consisting of C_{3-6} cycloalkyl and C_{4-8} heterocyclyl, each of which is optionally further substituted with one to four substituents independently selected from the group consisting of oxo, OH, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} hydroxyalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, C_{1-4} hydroxyalkoxy, SO_2NH_2, $CONH_2$, C(O)NHOH, PO_3H_2, COO-C_{1-8}alkyl, SO_3H, and CO_2H.

21. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein A is –C(=O)N(R^a)- and Z is a 5- or 6-membered non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with R^a and/or R^b.

22. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein A is –C(=O)N(R^a)- and Z is a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three R^c.

23. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein A is –C(=O)N(R^a)-; Z is a 5- or 6-membered non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with R^a and/or R^b; and each of R^{1c}, R^6, R^7, and R^8 is H.

24. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein A is –C(=O)N(R^a)-; Z is a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three R^c; and each of R^{1c}, R^6, R^7, and R^8 is H.

25. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein A is –C(=O)N(R^a)-; Z is a 5- or 6-membered non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with R^a and/or R^b; and said non-aromatic heterocyclic ring is selected from the group consisting of piperidinyl, morpholinyl, tetrahydropyranyl, and tetrahydrofuranyl.

26. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein A is –C(=O)N(R^a)-; Z is a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three R^c; and said heteroaryl ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, oxazolyl, thiazolyl, and pyrazolyl.

27. The compound of claim **1**, which is selected from:

Cmpd. No.	Structure
1.001	
1.002	

Cmpd. No.	Structure
1.003	
1.004	
1.005	
1.006	
1.007	
1.008	
1.009	
1.010	

Cmpd. No.	Structure
1.011	
1.012	
1.013	
1.014	
1.015	
1.016	
1.017	

Cmpd. No.	Structure
1.018	
1.019	
1.020	
1.021	
1.022	
1.023	
1.024	
1.025	

Cmpd. No.	Structure
1.026	
1.027	
1.028	
1.029	
1.030	
1.031	
1.032	
1.033	
1.034	

Cmpd. No.	Structure
1.035	
1.036	
1.037	
1.038	
1.039	
1.040	
1.041	
1.042	

Cmpd. No.	Structure
1.043	
1.044	
1.045	
1.046	
1.047	
1.048	
1.049	
1.050	

Cmpd. No.	Structure
1.051	
1.052	
1.053	
1.054	
1.055	
1.056	
1.057	
1.058	

Cmpd. No.	Structure
1.059	
1.060	
1.061	
1.062	
1.063	
1.064	
1.065	
1.066	

Cmpd. No.	Structure
1.067	
1.068	
1.069	
1.070	
1.071	
1.072	
1.073	

Cmpd. No.	Structure
1.074	
1.075	
1.076	
1.077	
1.078	
1.079	
1.080	

Cmpd. No.	Structure
1.081	
1.082	
1.083	
1.084	
1.085	
1.086	
1.087	
1.088	

Cmpd. No.	Structure
1.089	
1.090	
1.091	
1.092	
1.093	
1.094	
1.095	
1.096	

Cmpd. No.	Structure
1.097	
1.098	
1.099	
1.100	
1.101	
1.102	
1.103	
1.104	

Cmpd. No.	Structure
1.105	
1.106	
1.107	
1.108	
1.109	
1.110	
1.111	
1.112	

Cmpd. No.	Structure
1.113	
1.114	
1.115	
1.116	
1.117	
1.118	
1.119	
1.120	

Cmpd. No.	Structure
1.121	
1.122	
1.123	
1.124	
1.125	
1.126	
1.127	

Cmpd. No.	Structure
1.128	
1.129	
1.130	
1.131	
1.132	
1.133	
1.134	

Cmpd. No.	Structure
1.135	
1.136	
1.137	
1.138	
1.139	
1.140	
1.141	

Cmpd. No.	Structure
1.142	
1.143	
1.144	
1.145	
1.146	
1.147	
1.148	

Cmpd. No.	Structure
1.149	
1.150	
1.151	
1.152	
1.153	
1.154	
1.155	

Cmpd. No.	Structure
1.156	
1.157	
1.158	
1.159	
1.160	
1.161	
1.162	
1.163	

Cmpd. No.	Structure
1.164	
1.165	
1.166	
1.167	
1.168	
1.169	
1.170	

Cmpd. No.	Structure
1.171	
1.172	
1.173	
1.174	
1.175	
1.176	
1.177	

Cmpd. No.	Structure
1.178	
1.179	
1.180	
1.181	
1.182	
1.183	
1.184	

Cmpd. No.	Structure
1.185	
1.186	
1.187	
1.188	
1.189	
1.190	
1.191	

Cmpd. No.	Structure
1.192	
1.193	
1.194	
1.195	
1.196	
1.197	
1.198	
1.199	

Cmpd. No.	Structure
1.200	
1.201	
1.202	
1.203	
1.204	
1.205	
1.206	
1.207	

Cmpd. No.	Structure
1.208	
1.209	
1.210	
1.211	
1.212	
1.213	
1.214	
1.215	

Cmpd. No.	Structure
1.216	
1.217	
1.218	
1.219	
1.220	
1.221	
1.222	
1.223	

Cmpd. No.	Structure
1.224	
1.225	
1.226	
1.227	
1.228	
1.229	
1.230	
1.231	

Cmpd. No.	Structure
1.232	
1.233	
1.234	
1.235	
1.236	
1.237	
1.238	
1.239	

Cmpd. No.	Structure
1.240	
1.241	
1.242	
1.243	
1.244	
1.245	
1.246	
1.247	
1.248	

Cmpd. No.	Structure
1.249	
1.250	
1.251	
1.252	
1.253	
1.254	
1.255	
1.256	

Cmpd. No.	Structure
1.257	
1.258	
1.259	
1.260	
1.261	
1.262	
1.263	
1.264	

Cmpd. No.	Structure
1.265	
1.266	
1.267	
1.268	
1.269	
1.270	
1.271	
1.272	

Cmpd. No.	Structure
1.273	
1.274	
1.275	
1.276	
1.277	
1.278	
1.279	

Cmpd. No.	Structure
1.280	
1.281	
1.282	
1.283	
1.284	
1.285	
1.286	

Cmpd. No.	Structure
1.287	
1.288	
1.289	
1.290	
1.291	
1.292	
1.293	

Cmpd. No.	Structure
1.294	
1.295	
1.296	
1.297	
1.298	
1.299	
1.300	

Cmpd. No.	Structure
1.301	
1.302	
1.303	
1.304	
1.305	
1.306	
1.307	
1.308	

Cmpd. No.	Structure
1.309	
1.310	
1.311	
1.312	
1.313	
1.314	
1.315	
1.316	

Cmpd. No.	Structure
1.317	
1.318	
1.319	
1.320	
1.321	
1.322	
1.323	
1.324	

Cmpd. No.	Structure
1.325	
1.326	
1.327	
1.328	
1.329	
1.330	
1.331	
1.332	

Cmpd. No.	Structure
1.333	
1.334	
1.335	
1.336	
1.337	
1.338	
1.339	
1.340	

Cmpd. No.	Structure
1.341	
1.342	
1.343	
1.344	
1.345	
1.346	
1.347	
1.348	
1.349	

Cmpd. No.	Structure
1.350	
1.351	
1.352	
1.353	
1.354	
1.355	
1.356	
1.357	
1.358	

Cmpd. No.	Structure
1.359	
1.360	
1.361	
1.362	
1.363	
1.364	
1.365	
1.366	
1.367	

Cmpd. No.	Structure
1.368	
1.369	
1.370	
1.371	
1.372	
1.373	
1.374	
1.375	

Cmpd. No.	Structure
1.376	
1.377	
1.378	
1.379	
1.380	
1.381	
1.382	

Cmpd. No.	Structure
1.383	
1.384	
1.385	
1.386	
1.387	
1.388	
1.389	
1.390	

Cmpd. No.	Structure
1.391	
1.392	
1.393	
1.394	
1.395	
1.396	
1.397	
1.398	
1.399	

Cmpd. No.	Structure
1.400	
1.401	
1.402	

or a pharmaceutically acceptable salt thereof.

28. The compound of claim **1**, which is selected from

Cmpd. No.	Structure
2.001	
2.002	
2.003	
2.004	

Cmpd. No.	Structure
2.005	
2.006	
2.007	
2.008	
2.009	
2.010	
2.011	

Cmpd. No.	Structure
2.012	
2.013	
2.014	
2.015	
2.016	
2.017	
2.018	

Cmpd. No.	Structure
2.019	
2.020	
2.021	
2.022	
2.023	
2.024	
2.025	

Cmpd. No.	Structure
2.026	
2.027	
2.028	
2.029	
2.030	
2.031	
2.032	

Cmpd. No.	Structure
2.033	
2.034	
2.035	
2.036	
2.037	
2.038	
2.039	

Cmpd. No.	Structure
2.040	
2.041	
2.042	
2.043	
2.044	
2.045	
2.046	

Cmpd. No.	Structure
2.047	
2.048	
2.049	
2.050	
2.051	
2.052	
2.053	

Cmpd. No.	Structure
2.054	
2.055	
2.056	
2.057	
2.058	
2.059	
2.060	

Cmpd. No.	Structure
2.061	
2.062	
2.063	
2.064	
2.065	
2.066	
2.067	

Cmpd. No.	Structure
2.068	
2.069	
2.070	
2.071	
2.072	
2.073	
2.074	

Cmpd. No.	Structure
2.075	
2.076	
2.077	
2.078	
2.079	
2.080	
2.081	

Cmpd. No.	Structure
2.082	
2.083	
2.084	
2.085	
2.086	
2.087	
2.088	

Cmpd. No.	Structure
2.089	
2.090	
2.091	
2.092	
2.093	
2.094	
2.095	

Cmpd. No.	Structure
2.096	
2.097	
2.098	
2.099	
2.100	
2.101	
2.102	

Cmpd. No.	Structure
2.103	
2.104	
2.105	
2.106	
2.107	
2.108	
2.109	

Cmpd. No.	Structure
2.110	
2.111	
2.112	
2.113	
2.114	
2.115	

or a pharmaceutically acceptable salt thereof.

29. The compound of claim **1**, which is



,

or a pharmaceutically acceptable salt thereof.

30. The compound of claim **1**, which is



,

or a pharmaceutically acceptable salt thereof.

31. The compound of claim **1**, which is



,

or a pharmaceutically acceptable salt thereof.

32. The compound of claim **1**, which is



,

or a pharmaceutically acceptable salt thereof.

33. A pharmaceutical composition comprising a compound of any one of claims **1** to **32**, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

34. Use of a compound of any one of claims **1** to **32**, or a pharmaceutically acceptable salt thereof, or a composition of claim **33** in the preparation of a medicament for treating a subject suffering from or susceptible to an infectious disease, a bacterial infectious disease, a viral infectious disease, a fungal infectious disease, a solid tumor, a hematological malignancy, an immune disorder, an inflammatory disease, and cancer.

35. Use of a compound of any one of claims **1** to **32**, or a pharmaceutically acceptable salt thereof, or a composition of claim **33** in the preparation of a medicament for treating a subject suffering from or susceptible to a disease or disorder selected from the group consisting of melanoma, glioblastoma, esophagus tumor, nasopharyngeal carcinoma, uveal melanoma, lymphoma, lymphocytic lymphoma, primary CNS lymphoma, T-cell lymphoma, diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, prostate cancer, castration-resistant prostate cancer, chronic myelocytic leukemia, Kaposi's sarcoma fibrosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, angiosarcoma, lymphangiosarcoma, synovioma, meningioma, leiomyosarcoma, rhabdomyosarcoma, sarcoma of soft tissue, sarcoma, sepsis, biliary tumor, basal cell carcinoma, thymus neoplasm, cancer of the thyroid gland, cancer of the parathyroid gland, uterine cancer, cancer of the adrenal gland, liver infection, Merkel cell carcinoma, nerve tumor, follicle center lymphoma, colon cancer, Hodgkin's disease, non-Hodgkin's lymphoma, leukemia, chronic or acute leukemias, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, ovary tumor, myelodysplastic syndrome, cutaneous or intraocular malignant melanoma, renal cell carcinoma, small-cell lung cancer, lung cancer, mesothelioma, breast cancer, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, colorectal cancer, ovarian cancer, gastric cancer, hepatocellular carcinoma, pancreatic carcinoma, pancreatic cancer, pancreatic ductal adenocarcinoma, squamous cell carcinoma of the head and neck, cancer of the head or neck, gastrointestinal tract, stomach cancer, HIV, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, herpes viruses, papillomaviruses, influenza, bone cancer, skin cancer, rectal cancer, cancer of the anal region, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the urethra, cancer of the penis, cancer of the

bladder, cancer of the kidney, cancer of the ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, epidermoid cancer, abestosis, carcinoma, adenocarcinoma, papillary carcinoma, cystadenocarcinoma, bronchogenic carcinoma, renal cell carcinoma, transitional cell carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms tumor, pleomorphic adenoma, liver cell papilloma, renal tubular adenoma, cystadenoma, papilloma, adenoma, leiomyoma, rhabdomyoma, hemangioma, lymphangioma, osteoma, chondroma, lipoma, and fibroma.